Compare Stocks → Move Your Money Before May 1 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MTEMNASDAQ:ORGSNASDAQ:SYRSNASDAQ:ZYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTEMMolecular Templates$1.72+7.5%$2.58$1.40▼$9.45$9.24M1.1552,544 shs69,212 shsORGSOrgenesis$0.51$0.65$0.25▼$1.50$17.42M1.07213,963 shs24,467 shsSYRSSyros Pharmaceuticals$5.04-1.2%$6.09$2.09▼$8.17$134.72M1.74211,673 shs44,534 shsZYNEZynerba Pharmaceuticals$1.30+2.4%$1.30$0.25▼$1.40$70.12M1.32515,333 shs862,700 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTEMMolecular Templates-3.05%+7.07%-30.57%-55.40%-73.21%ORGSOrgenesis+2.17%+2.58%-39.74%+65.19%-54.00%SYRSSyros Pharmaceuticals+0.59%+8.05%-18.40%-25.76%+61.90%ZYNEZynerba Pharmaceuticals0.00%0.00%0.00%0.00%+246.57%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMTEMMolecular Templates1.0809 of 5 stars0.02.00.04.61.14.20.0ORGSOrgenesis0.7304 of 5 stars0.03.00.04.41.61.70.0SYRSSyros Pharmaceuticals3.8457 of 5 stars3.51.00.04.31.13.30.6ZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTEMMolecular TemplatesN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/ASYRSSyros Pharmaceuticals3.00Buy$14.33184.39% UpsideZYNEZynerba Pharmaceuticals2.00Hold$1.11-14.62% DownsideCurrent Analyst RatingsLatest ZYNE, SYRS, ORGS, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024SYRSSyros PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.004/1/2024SYRSSyros PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTEMMolecular Templates$57.31M0.16N/AN/A$0.78 per share2.21ORGSOrgenesis$530K32.87N/AN/A($0.66) per share-0.77SYRSSyros Pharmaceuticals$9.94M13.55N/AN/A$0.79 per share6.38ZYNEZynerba PharmaceuticalsN/AN/AN/AN/A$1.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTEMMolecular Templates-$8.12M-$1.55N/AN/AN/A-14.18%-9,335.53%-20.51%5/20/2024 (Estimated)ORGSOrgenesis-$55.36M-$0.91N/A∞N/A-91.25%-590.97%-126.17%5/8/2024 (Estimated)SYRSSyros Pharmaceuticals-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)ZYNEZynerba Pharmaceuticals-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/ALatest ZYNE, SYRS, ORGS, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023MTEMMolecular Templates-$2.10-$0.73+$1.37-$0.73N/A$7.02 million3/27/2024Q4 2023SYRSSyros Pharmaceuticals-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMTEMMolecular TemplatesN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ASYRSSyros PharmaceuticalsN/AN/AN/AN/AN/AZYNEZynerba PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTEMMolecular TemplatesN/A0.970.97ORGSOrgenesis1.480.250.25SYRSSyros Pharmaceuticals2.073.953.95ZYNEZynerba PharmaceuticalsN/A3.433.43OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTEMMolecular Templates95.47%ORGSOrgenesis22.56%SYRSSyros Pharmaceuticals91.47%ZYNEZynerba Pharmaceuticals11.23%Insider OwnershipCompanyInsider OwnershipMTEMMolecular Templates18.70%ORGSOrgenesis7.14%SYRSSyros Pharmaceuticals10.45%ZYNEZynerba Pharmaceuticals13.04%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMTEMMolecular Templates1115.37 million4.37 millionNo DataORGSOrgenesis16734.35 million31.90 millionOptionableSYRSSyros Pharmaceuticals6826.73 million23.94 millionOptionableZYNEZynerba Pharmaceuticals2553.94 million46.91 millionOptionableZYNE, SYRS, ORGS, and MTEM HeadlinesSourceHeadlineHarmony Biosciences Reports Strong Third Quarter 2023 Financial Resultsfinance.yahoo.com - October 31 at 7:57 AMWhy Shares of Harmony Bioscience Are Falling on Fridayfool.com - October 13 at 12:59 PMNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapiesmarkets.businessinsider.com - October 11 at 9:47 AMHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEfinance.yahoo.com - October 11 at 9:47 AMH.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 10 at 1:59 PMAnalysts: ZYNE stock price target of $1.25 in 12 monthsknoxdaily.com - October 5 at 6:47 PMImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructionsfinance.yahoo.com - October 4 at 7:33 PMExamining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE)knoxdaily.com - October 2 at 3:14 PM20 Countries With Highest Rate of Epilepsyfinance.yahoo.com - September 29 at 6:24 PMZynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023finance.yahoo.com - September 29 at 1:23 PMHarmony Biosciences extends deadline for Zynerba shareholders on up to $200M dealbizjournals.com - September 27 at 2:42 PMZynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Riseknoxdaily.com - September 25 at 8:15 PMZynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwrightknoxdaily.com - September 20 at 12:12 PMNegative sentiment towards ZYNE reflected in surge in short interestknoxdaily.com - September 15 at 8:27 PMInsider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Incfinance.yahoo.com - September 14 at 11:23 PMZynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposiumfinance.yahoo.com - September 14 at 6:23 PMZynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statementlaw.com - September 11 at 4:04 PMPositive sentiment towards ZYNE reflected in decline in short interestknoxdaily.com - September 8 at 5:19 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLRbakersfield.com - August 31 at 5:00 PMHC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)msn.com - August 16 at 4:20 AMHarmony Makes Rare Disease Play with Potential $200M Zynerba Buyoutbiospace.com - August 15 at 6:19 PMZynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much?dhakatribune.com - August 15 at 6:19 PMIs Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 15 at 6:19 PMZynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNEmarketwatch.com - August 14 at 9:48 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMolecular TemplatesNASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.OrgenesisNASDAQ:ORGSOrgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.Syros PharmaceuticalsNASDAQ:SYRSSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Zynerba PharmaceuticalsNASDAQ:ZYNEZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.